SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ...
Since their discovery in 2006 by Takahashi and Yamanaka, induced pluripotent stem cells (iPSCs) have seen a remarkable surge in their application within academic and industrial research. Generated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results